In a pilot study, it was determined that treating cervical cancer patients with celecoxib (400 mg twice daily/10 days) decreased the expression of COX-2, Ki-67, PGE2, and microvessel density in tumor biopsies [182]. Here, PTGS2 is linked to cervical cancer.